Company / Cash & Equivalents
Moderna Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$2.6B
FY2025
5-year range
$1.9B / $6.8B
FY2021-FY2025
Trend
+34.7%
vs FY2024
Sector context
#12 of 207
Health Care
What the data says
Among 207 Health Care companies, Moderna is in the top 6% for cash & equivalents. Cash & Equivalents returned to growth in FY2025 after 2 years of decline, reaching $2.6B.
Based on SEC 10-K filings.
$2.6B in FY2025 with a 5-year CAGR of -0.2%. Top quartile in the Health Care sector.
Declined from $2.9B to $2.6B over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -27.6%
- 5-Year CAGR
- -0.2%
- 10-Year CAGR
- -
Sector benchmark
Top 6% in Health CareTop 6% of 207This company $2.6B Sector average $669.5M
▼
+287.6% above sector average
Key checks
Key Insights
- 5-year CAGR of -0.2%, indicating a declining trend.
- In FY2025, cash & equivalents increased 34.7% year-over-year.
- Ranks #12 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 1.13 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.6B | +34.7% |
| FY2024 | $1.9B | -33.7% |
| FY2023 | $2.9B | -57.5% |
| FY2022 | $6.8B | +161.0% |
| FY2021 | $2.6B | +0.0% |
| FY2020 | $2.6B | +1011.9% |
| FY2019 | $236.0M | -64.2% |
| FY2018 | $658.4M | +388.2% |
| FY2017 | $134.9M | +169.3% |
| FY2016 | $50.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026